Literature DB >> 15280674

Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols.

Robert A Montgomery1, Mark A Hardy, Stanley C Jordan, Lorraine C Racusen, Lloyd E Ratner, Dolly B Tyan, Andrea A Zachary.   

Abstract

During the past few decades, much of the experimental and clinical effort in solid-organ transplantation has been directed toward ameliorating or abrogating T-cell-mediated responses. As a result, universally understood and accepted nomenclature and diagnostic criteria have evolved. Humoral immunity in transplantation has yet to undergo a similar renaissance. Readers of transplant journals regularly find it difficult and often impossible to interpret data on the diagnosis and management of antibody-mediated rejection. The Antibody Working Group was assembled in an attempt to provide guidelines for the standardization of nomenclature, diagnostic criteria, reporting, antibody profiling, and risk assessment.

Mesh:

Substances:

Year:  2004        PMID: 15280674     DOI: 10.1097/01.tp.0000129256.84027.d6

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  14 in total

1.  A case of desensitization, transplantation, and allograft dysfunction.

Authors:  Colm Magee; Michael Clarkson; Helmut Rennke
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

Review 2.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

Review 3.  Treatment options and strategies for antibody mediated rejection after renal transplantation.

Authors:  Matthew H Levine; Peter L Abt
Journal:  Semin Immunol       Date:  2011-09-21       Impact factor: 11.130

4.  The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

Authors:  A I Musat; R M Agni; P Y Wai; J D Pirsch; D F Lorentzen; A Powell; G E Leverson; J M Bellingham; L A Fernandez; D P Foley; J D Mezrich; A M D'Alessandro; M R Lucey
Journal:  Am J Transplant       Date:  2011-03       Impact factor: 8.086

5.  Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation.

Authors:  Nataraju Angaswamy; Deepti Saini; Sabarinathan Ramachandran; Dilip S Nath; Donna Phelan; Ramsey Hachem; Elbert Trulock; G Alexander Patterson; T Mohanakumar
Journal:  Hum Immunol       Date:  2010-03-16       Impact factor: 2.850

6.  Rituximab in the treatment of acute cellular rejection of renal allograft with CD20-positive clusters in the infiltrate.

Authors:  Jorge Vega; Helmuth Goecke; Alejandra Carrasco; Carlos Escobar; Max Escobar; Roberto Espinosa; Gonzalo Méndez; María de Los Ángeles Rodríguez
Journal:  Clin Exp Nephrol       Date:  2010-12-10       Impact factor: 2.801

Review 7.  Renal transplantation in high-risk patients.

Authors:  Nicole A Weimert; Rita R Alloway
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients.

Authors:  F Ahmadi; S Dashti-Khavidaki; M R Khatami; M Gatmiri; F Ahmadi; M Mahdavi-Mazdeh; M T Najafi; Z Foroozanfar; A Mahdizadeh; S Derafshi
Journal:  Int J Organ Transplant Med       Date:  2019

9.  Renal allograft pathology with C4d immunostaining in patients with graft dysfunction.

Authors:  M Mubarak
Journal:  Indian J Nephrol       Date:  2012-05

10.  Renal transplantation across ABO barrier.

Authors:  P N Gupta; S Pokhariyal; S Bansal; S Jain; V Saxena; R Sharma; M Jain; P Jha; S K Sethi; P Ghosh; A Tewari; R Ahlawat; V Kher
Journal:  Indian J Nephrol       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.